Clinical studies of adoptive immunochemotherapy combined with anti-cancer agents in the treatment of malignant bone tumor

过继性免疫化疗联合抗癌药物治疗恶性骨肿瘤的临床研究

• 批准号: 05671210
• 负责人: TAKTEUCHI Shoji
• 金额: $ 1.22万
• 依托单位: Gifu University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1993
• 资助国家: 日本
• 起止时间: 1993 至 1994
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-05671210/
• 关键词: malignant bone tumor; anti-cancer agent; BRM; immunochemotherapy; intra-arterial infusion chemotherapy; サイトカイン

In order to evaluate the biological response after intraarterial and intravenous administration anti-cancer agents, we studied the changes of cytokine levels in serum.Four types of cytokines (IL-1beta, IL-2, IL-6, TNF-alpha) were measured by ELISA method. A significant increase of IL-6 and TNF-alpha production was observed after intravenous infusion of anti-cancer agents.After intraarterial infusion of agents there was a slight increase in the production of these cytokines.On the other hand, there were no changes in the IL-1beta and IL-2 levels after infusion of the agents.IL-6 and TNF-alpha increased almost at the same time that the numbers of WBC decreased after infusion.And this phenomenon was clear in the patients who had a good performance status.Further studies should be done to confirm the efficacy of the adoptive immunochemotherapy combined with anti-cancer agents for malignat bone tumor.

为了评价动脉和静脉注射抗癌药物后的生物学反应，我们研究了血清中细胞因子水平的变化。采用ELISA方法测定了四种细胞因子（IL-1β、IL-2、IL-6、TNF-α）。静脉输注抗癌药物后，观察到IL-6和TNF-α的产生显着增加。动脉内输注药物后，这些细胞因子的产生略有增加。另一方面，输注药物后IL-1β和IL-2水平没有变化。IL-6和TNF-α几乎与WBC数量同时增加 输注后下降。这种现象在体能状态良好的患者中更为明显。过继性免疫化疗联合抗癌药物治疗恶性骨肿瘤的疗效还需进一步研究证实。